2023 Fiscal Year Final Research Report
Development of Novel Gastrointestinal Cancer Therapy by Targeting Ubiquitin Proteasome Systems
| Project/Area Number |
21K16483
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 55020:Digestive surgery-related
|
|---|
| Research Institution | Nara Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2021-04-01 – 2024-03-31
|
| Keywords | ユビキチンプロテアソームシステム |
|---|
| Outline of Final Research Achievements |
Cancer treatment has advanced significantly with the development of new anticancer drugs, leading to improved outcomes for many cancer types. However, treatment-resistant advanced or recurrent gastrointestinal cancers still have a poor prognosis. This study examined the potential of UBR5, an E3 ubiquitin ligase, as a novel therapeutic agent.
We assessed the expression level of UBR5 using real-time PCR and immunohistochemistry in untreated gastric cancer specimens. Despite multiple validations under different conditions, we found no difference in expression levels between lesional and non-lesional areas, and the overall expression level was low. These results suggest that UBR5 expression is low in gastric cancer, unlike in other cancers.
|
| Free Research Field |
上部消化管癌
|
| Academic Significance and Societal Importance of the Research Achievements |
これまでにUBR5が乳癌や膀胱癌などの悪性腫瘍で過剰発現していることが報告され、卵巣癌においては過剰発現が予後不良因子であり薬剤抵抗性と関連していることが示され，乳癌・膀胱癌においては腫瘍細胞増殖と転移に関連していることが明らかとなっている．
しかし、今回の未治療胃癌切除検体における検証では，UBR5はリアルタイムPCR，免疫組織染色を行っても病変部での発現は強く認めなかった．よって，胃癌においては治療標的としての意義は低いことが明らかになった．
|
